HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

NXL

Nexalin Technology, Inc. (NASDAQ)

Healthcare — Medical Devices

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.

None 1 analysts
$0.38
+$0.05 (+15.15%)
Target: $2.00 (426.3%)
Sign in to add NXL to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$8.19M
P/E Ratio (TTM)-
Forward P/E-1.23
EPS (TTM)$-0.46
Dividend Yield-
Profit Margin-
Revenue Growth-63.60%
ROE-319.69%
Debt/Equity-
Recommendation None
Analyst Target$2.00
Analysts1
Indexes NASDAQ

Technical Indicators

RSI (14)34.5
Beta3.84
SMA 20-
SMA 40-
52-Week High$2.00
52-Week Low$0.31
50-Day Avg$0.41
200-Day Avg$0.70
Avg Volume871.9K
Volume329.0K

Performance Analysis

NEUTRAL

NXL presents a mixed picture with both positive and negative indicators.

+ Trading near its 52-week low ($0.30), which could present a value opportunity.
~ RSI at 34.5 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
- Revenue declined 63.6% year-over-year.
~ Wall Street consensus is "none" from 1 analysts.
+ Average analyst target of $2.00 implies 426.3% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:23 UTC

Back to Screener Export Report